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Contrast-enhanced magnetic resonance
imaging of the breast: the value
of pharmacokinetic parameters derived
from fast dynamic imaging during initial
enhancement in classifying lesions
Abstract The value of pharmacoki-
netic parameters derived from fast
dynamic imaging during initial en-
hancement in characterizing breast
lesions on magnetic resonance imag-
ing (MRI) was evaluated. Sixty-eight
malignant and 34 benign lesions were
included. In the scanning protocol,
high temporal resolution imaging was
combined with high spatial resolution
imaging. The high temporal resolution
images were recorded every 4.1 s
during initial enhancement (fast dy-
namic analysis). The high spatial res-
olution images were recorded at a
temporal resolution of 86 s (slow
dynamic analysis). In the fast dynamic
evaluation pharmacokinetic param-
eters (K
trans,V e and kep) were eval-
uated. In the slow dynamic analysis,
each lesion was scored according to
the BI-RADS classification. Two
readers evaluated all data prospec-
tively. ROC and multivariate analysis
were performed. The slow dynamic
analysis resulted in an AUC of 0.85
and 0.83, respectively. The fast dy-
namic analysis resulted in an AUC of
0.83 in both readers. The combination
of both the slow and fast dynamic
analyses resulted in a significant
improvement of diagnostic perfor-
mance with an AUC of 0.93 and 0.90
(P=0.02). The increased diagnostic
performance found when combining
both methods demonstrates the addi-
tional value of our method in further
improving the diagnostic performance
of breast MRI.
Keywords Breast . MR . Dynamic .
Pharmacokinetic
Introduction
Breast cancer is the most commonly diagnosed cancer in
women and the most prevalent cancer worldwide [1]. In
breast imaging, mammography is still the most commonly
usedimagingtechniquesbothinscreeningforandstagingof
breast cancer. However, dynamic contrast-enhanced mag-
netic resonance imaging (MRI) is becoming an increasingly
important imaging modality in the detection and staging of
breast cancer. Because of its superior sensitivity for the
detection of invasive breast cancer, MRI has become a very
important modality in breast imaging [2–5].
However, the classification of a lesion detected on MRI
as benign or malignant still remains a challenge. Reported
specificities in clinical studies range between 20% and
100% [6–15]. The main characteristics used for classifica-
tion of detected lesions on MRI are the lesion morphology
and the enhancement dynamics [4]. Dynamic evaluation is
often based on late dynamic characteristics of enhancing
lesions. In this approach, the decrease of signal intensity,
often referred to as a type 3 curve or washout, is highly
suggestive for breast cancer with the likelihood for
malignancy of 87% [12]. This dynamic evaluation makes
use of high-resolution T1-weighted MRI images with a
relatively low time resolution of 42 s or more [3, 12, 16–
20]. The high spatial resolution of these sequences is
necessary for accurate morphologic evaluation. Irregular
lesion contour, inhomogeneous internal enhancement and
rim enhancement have been described as features indicat-
ing a malignancy [21].
Schnall et al. [4] found focal mass margins and signal
intensity to be a highly predictive imaging features.
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phological parameters resulted in the highest diagnostic
accuracy in multivariate analysis.
The evaluation of early enhancement using a high
temporal resolution has also been a subject of study in
breast MRI. Boetes et al. [6] found in a group of 87 lesions
a sensitivity of 95%, a specificity of 86% and an overall
accuracy of 93% based on early enhancement character-
istics. In this study, a temporal resolution of 2.3 s was
achieved using a turboFLASH sequence. The value of a
high temporal resolution during initial enhancement was
confirmed by Sardanelli et al. [22] who used a temporal
resolution of 15 s during the first minute of enhancement.
The overlap between malignant and benign enhancement
curves was only 9% using the fast dynamic evaluation
compared with 50% using a lower temporal resolution of
1 min.
The value of first pass high temporal resolution imaging
for the differentiation of benign and malignant lesions was
studied in a direct comparison of steady-state dynamic
MRI (30 s temporal resolution) and first-pass imaging (2 s
temporal resolution) of induced mammary tumors in
female rats by Helbich et al. [23]. In their study, an
estimate of first-pass perfusion using T2*-weighted imag-
ing almost reached a significant difference between benign
and malignant tumors. All other methods used, including
T1-weighted first-pass imaging, failed to differentiate
benign from malignant tumors. Gibbs et al. [24] also
used a high temporal resolution (10.5–14.5 s) in the
evaluation of small breast lesions and evaluated their data
using a pharmacokinetic model. The incorporation of data
from pharmacokinetic modeling in the evaluation of
lesions improved diagnostic accuracy in their group.
High temporal resolution sequences often cover a
limited area of the breast [6, 24]. These imaging protocols
are, therefore, less suitable in clinical MRI or screening.
For this study, we adjusted the scanning protocol in order to
obtain a high temporal resolution during initial enhance-
ment while covering both breasts entirely. The aim of this
study is to asses the value of pharmacokinetic parameters
derived from fast dynamic contrast enhanced imaging
during initial enhancement in differentiating between
benign and malignant breast lesions on MRI.
Materials and methods
Patient selection
All lesions detected on clinically performed breast MRI
examinations in the period from January 2004 until June
2005 were initially included. All detected lesions were
evaluated based on the following inclusion criteria: (1)
histological confirmed diagnosis or (2) follow-up based on
unchanged MRI morphology and enhancement character-
istics during at least 24 months indicating a benign nature
of the lesion [25]. Lesions that could not be classified as
benign or malignant using these criteria were excluded.
The protocol was approved by the institutional review
board.
Imaging protocol
All patients were examined using a 1.5-Tesla MRI scanner
(Sonata or Symphony, Siemens, Erlangen, Germany) in
combination with a double breast coil. In premenopausal
women, the MRI examination was performed in the second
week of the menstrual cycle to minimize enhancement of
normal glandular tissue [26]. Prior to the MRI examination,
an intravenous catheter was inserted in the left or right arm.
All patients were placed in the prone position with the
breasts in the double breast coil and positioned at the
isocenter of the magnet. After localizer images were
obtained in three directions, low spatial resolution proton-
density-weighted images were acquired in the transverse
plane covering both breasts completely (TE 1.56, TR 800,
FA 8, FOV 320, slices 24, TA 50 s, image resolution
3.9 mm×1.3 mm×4.0 mm). Subsequently, a coronally
orientated high-resolution three-dimensional fast low-
angle shot series (FLASH 3D) was acquired (TE 4, TR
7.5, FA 8, FOV 320, slices 120, TA 86 s, image resolution
1.3 mm×1.3 mm×1.3 mm). Thereafter, high temporal
resolution T1-weighted images (turboFLASH) were re-
corded 22 times with identical spatial resolution and
orientation as the proton-density-weighted images (TE
1.56, TR 66, FA 20, FOV 320, slices 24, TA 22×4.1 s)
during an intravenous bolus injection of a paramagnetic
gadolinium chelate—0.2 mmol of gadoterate meglumine
(Dotarem; Guerbet, The Netherlands) per kilogram of body
weight—which was administered with a power injector
(Spectris; Medrad, Pittsburg, USA) at 2.5 ml/s and
followed by a 15-ml saline flush. Following these series,
the FLASH 3D series was repeated four times. Total scan
time for this protocol was 9 min 42 s, including the time
needed to record localizer images.
Image evaluation
For the evaluation, the MRI data were divided into two sets
of dynamic data for each patient. The first dataset contained
the high spatial resolution T1-weighted images (FLASH
3D) only. These were used for the evaluation of both lesion
morphology as well as signal intensity versus time curves.
This method will be further referred to as the ‘slow
dynamic’ analysis. The second dataset contained the
proton-density-weighted images, the high temporal reso-
lution images as well as the precontrast high spatial
resolution sequence. A high-resolution subtraction of the
pre- and first postcontrast FLASH3D series prepared on the
MRI scanner was also included in this dataset to aid in
1124lesion detection. The proton-density-weighted sequence
was necessary for an accurate estimation of the T1 value
necessary for the quantitative analyses. The evaluation of
this dataset will be further referred to as the ‘fast dynamic’
analysis. In this fast dynamic analysis, the last three
postcontrast FLASH 3D series were not used.
All cases were evaluated prospectively by two experi-
enced breast MRI radiologists (reader 1 and reader 2). Both
readers had over 5 years of experience in dynamic breast
MRI. The evaluation on the two workstations was
performed independently in different sessions with at
least a 2-month time interval between both sessions.
For the slow dynamic analysis, a dedicated breast MRI
workstation was used (Dynacad, Invivo, Germany). This
workstation creates subtraction images for all time points
after contrast administration, of which the first is
automatically displayed together with the precontrast T1
acquisition, both in a coronal orientation. Furthermore,
axial reconstructions were displayed for both the subtracted
and T1-weighted images with color overlays of wash-in/
wash-out enhancement characteristics projected over the
T1-weighted images [27]. A maximum intensity projection
and signal intensity versus time curves were also displayed.
This display protocol resembles the protocol used in the
clinical workflow of dynamic breast MRI in our hospital. A
BI-RADS classification was assigned for each lesion based
on their morphology and enhancement dynamics [28]. No
clinical information, mammography or prior MRI data
were provided to the readers during the evaluation of the
cases.
In the fast dynamic analysis, a workstation, developed
in-house for the evaluation of dynamic contrast enhanced
MRI, was used [29, 30]. On this workstation, pharmaco-
kinetic parameters derived from the high temporal resolu-
tion turboFLASH series were automatically calibrated,
calculated and displayed using color overlays. Examples of
the recorded high temporal resolution enhancement versus
time curves are presented in Fig. 1. In the preparation of
this high temporal resolution data, each MRI signal
enhancement/time curve was first fitted to a general
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Fig. 1 Relative enhancement
versus time curves of a benign
(a) and malignant (b) lesion.
Note that the slope of enhance-
ment and the level of enhance-
ment is higher for the malignant
lesion compared with the benign
lesion. These fast dynamic ac-
quisitions were analyzed as de-
scribed in the Materials and
methods section and resulted in
the color overlays as presented
in Figs. 4 and 5. The data used
in this figure were respectively
derived from a histopathology
proven fibroadenoma and an
invasive ductal carcinoma. The
same lesions as presented in
Figs. 4 and 5
1125exponential signal enhancement model, as described
previously [31]. This reduces a curve to model with the
following five parameters: baseline (s0); start of signal
enhancement (t0), which defines the onset of the exponen-
tial curve; time-to-peak (ttp), the exponential constant;
peak enhancement (sp), the signal amplitude at which the
exponential curve levels off; and late wash, defined as the
slope of the late part of the exponential curve. The reduced
signal enhancement/time curve was converted to a reduced
tracer concentration (mmol/ml)/time curve [31, 32], ef-
fectively converting sp to concentration tracer after initial
rapid wash-in (often at a peak or plateau level) (Cgd,p). The
reduced plasma concentration time curve was estimated
usingthe referencetissue method [33]. Deconvolution of the
plasmaprofileandestimationofpharmacokineticparameters
conformed to the theoretical derivations [34], but was
implemented in the reduced signal space as: Ve=Cgd,ptissue/
Cgd,pplasma;k ep=1/(ttptissue – ttpplasma). K
trans=V e ×K ep.
Where Ve is an estimate of the extracellular volume [%],
K
trans,the volume transfer constant (1/min), and kep,t h e
rate constant (1/min), between extracellular extravascu-
lar and plasma space. The subscript ‘tissue’ stands
for a measurement in the tissue under investigation and
the subscript ‘plasma’ for the reference tissue plasma
estimate. The reference tissue was automatically de-
termined by selecting a set of voxels in the whole
image volume [relative enhancement, (sp-s0)/s0] larger
than 0.2 and smaller than 2.0). This was most often the
pectoral muscle, sometimes the liver or spleen. The
additionally recorded proton density images were used
to correct for the coil profile. The data were presented
on the workstation with high-resolution precontrast T1-
weighted images in an axial, coronal and sagital
reconstruction (FLASH 3D) as background. Color
overlays were projected over the images representing
K
trans,k ep and Ve parameter values that were based on
the high temporal resolution images (turboFLASH). A
subtraction image based on the pre- and first postcon-
trast FLASH 3D series was presented to aid in lesion
detection. No criteria for differentiating between benign
and malignant lesions were derived from the subtracted
images. In this evaluation, the readers selected a region
of interest (ROI) within the enhancing lesion. The ROIs
were sphere-shaped and placed in an area within the
lesion where the parameter values of K
trans,V ea n dk ep
were highest, based on the color-overlays. The outer
limit of the lesion was used as a boundary of the ROI to
rule out partial volume effects [35]. This method of ROI
selection has previously been referred to as a hotspot
method [36]. Each reader placed only one ROI per
lesion. From this ROI, the workstation calculated the
mean values for each of the pharmacokinetic parameters.
Again, no clinical information, mammography or prior
MRI data were provided to the readers during the
evaluation of the cases. In case of multifocality, the
tumor was analyzed as a single lesion.
Statistical analysis
Differences in pharmacokinetic parameter values between
the malignant and benign group were evaluated using an
independent sample t-test. The performance of both
methods was compared using a receiver operator charac-
teristic (ROC) analysis. From the slow dynamic analysis,
the reader’s final BI-RADS classification of the lesion was
used in the ROC evaluation; from the fast dynamic
analysis, the mean parameter values calculated from the
ROI selected by each reader were used. Multivariate
analysis was performed using logistic regression in order to
evaluate the possible additional value of both methods to
one another. Since the differentiation between benign and
malignant lesions is more difficult in smaller lesions a
subgroup of all lesions of 2 cm and smaller were also
separately evaluated. The comparison of the various
results, including the interobserver variability, was done
by using the area under the ROC curve (AUC) as an
estimate of diagnostic accuracy. A pairwise comparison
was performed to evaluate differences in the AUC. P
values <0.05 were considered to indicate statistical
significance.
Results
A total of 870 consecutive clinical breast MRI examina-
tions in 787 patients were performed. In these studies a
total of 188 lesions were detected. Eighty-six lesions could
not be included due to lack of histological diagnosis or
insufficient follow-up. This resulted in a total of 102
lesions in 96 patients; 34 benign and 68 malignant lesions.
The mean age was 51 years (range 28–74 years). Ninety-
four lesions were included based on histological evalua-
tion, eight lesions based on follow-up. Mean lesion size on
MRI for the malignant group was 32 mm (range 9–90 mm)
and this was 15 mm (range 5–50 mm) for the benign
Table 1 Histological composition of the benign and malignant
group of lesions (IDCinvasive ductal carcinoma, DCISductal
carcinoma in situ, ILCinvasive lobular carcinoma)
Benign (n=34) Malignant (n=68)
Fibroadenoma 11 IDC 47
Fibrosis 4 DCIS 14
Adenosis 3 ILC 7
Inflammation 2
Ductal papilloma 2
Scar tissue 1
Hyperplasia 1
Hamartoma 1
Radial scar 1
Follow-up 8
1126lesions. A total of 52 lesions were 2 cm or smaller; 25
malignant (mean lesion size 14 mm, range 6–20 mm) and
27 benign (mean lesion size 11 mm , range 5–20 mm).
The histological evaluation of the malignant lesions was
in 14 cases based only on the core biopsy, in 14 cases based
on an excision biopsy or breast saving surgery specimen
and in 40 cases based on the mastectomy specimen.
Histological proven benign lesions were in 19 cases based
on a core biopsy and in seven cases based on an excision
biopsy. Eight lesions were proven benign based on follow-
up, mean follow-up was 37 months (range 24–52 months).
The histological composition of the entire group is
summarized in Table 1.
Imaging results
In the slow dynamic analysis reader 1 classified 25 lesions
as a BI-RADS 2 (benign:malignant=22:3), seven as BI-
RADS 3 (4:3), 50 as BI-RADS 4 (6:44) and 20 an BI-
RADS 5 (2:18). This was respectively 33 (24:9), 12 (4:8),
41 (5:36) and 16 (1:15) for reader 2. The ROC analysis for
the slow dynamic analysis resulted in an AUC of 0.85
(95% CI=0.773–0.918) and 0.83 (95% CI=0.74–0.89) for
reader 1 and 2, respectively.
The mean volume of the ROIs selected by the readers in
the fast dynamic evaluation was 0.51 cm
3 for reader 1
(range 0.15–1.94 cm
3, SD 0.30) and 0.52 cm
3 for reader 2
(range 0.15–1.94 cm
3, SD 0.41). No significant difference
was found for ROI size (P=0.72). The pharmacokinetic
parameters used in the fast dynamic analysis showed a
significant difference between the benign and malignant
group for both readers (Table 2). The diagnostic perfor-
mance of the fast dynamic analysis resulted in an AUC for
K
trans of 0.82 (95% CI=0.735–0.905) and 0.82 (95% CI=
0.739–0.909) for reader 1 and 2. For Ve the AUC was 0.78
(95% CI=0.682–0.873) and 0.77 (95% CI=0.670–0.866)
and for the kep parameter 0.72 (95% CI=0.609–0.828) and
0.74 (95% CI=0.629–0.841) for reader 1 and 2, respec-
tively. Scatter plots of K
trans and V displaying the
parameter values of benign and malignant lesions found
in the two readers are provided in Fig. 2. The comparison
of the diagnostic performance from the slow dynamic
analysis with the single parameter fast dynamic analysis
Table 2 Mean pharmacokinetic parameter values categorized for
malignant and benign lesions per reader. All parameter values
proved significantly higher in the malignant group compared to the
benign group (P<0.01)
Benign
(n=34)
95% CI Malignant
(n=68)
95% CI
Reader 1 K
transa 1.2 0.9–1.4 2.3 2.1–2.6
Ve 41.6 34.9–48.3 63.9 58.6–69.1
kep
a 3.0 2.7–3.3 3.8 3.5–4.0
Reader 2 K
transa 1.3 1.0–1.5 2.5 2.2–2.8
Ve 44.6 37.2–52.0 67.1 62.0–72.3
kep
a 3.0 2.6–3.3 3.9 3.7–4.2
a1/min.
Fig. 2 Scatter plots from the extracellular volume (V) versus the
transfer constant (K
trans) for reader 1 (a) and reader 2 (b). Benign
and malignant cases were clustered. Clusters were summarized with
an iso-probability contour computed from the cluster mean and
covariance at a squared normalized radius of 2. The continuous-line
ellipsoid represents the benign subgroup, the dotted-line ellipsoid
represents the malignant subgroup
1127showed no significant differences for the K
trans and V
parameter. A significant difference was found for reader 1
between the slow dynamic analysis and the kep parameter
(P=0.02) , the slow dynamic analysis showing better
results. This was not found for reader 2 (P=0.08).
Combining the pharmacokinetic parameters (K
trans,K
ep
and V) in a multivariate analyses resulted in an AUC of
0.83 (95% CI=0.74–0.90) and 0.83 (95% CI=0.74–0.90)
for reader 1 and 2. No significant difference was found
between the multivariate fast dynamic and the slow
dynamic diagnostic performance (P=0.49 and P=0.85).
The multivariate analysis from all pharmacokinetic
parameters combined with the slow dynamic analysis
(combined analysis) resulted in an AUC of 0.93 (95%
CI=0.85–0.96) and 0.90 (95% CI=0.83–0.95) for reader
1 and 2, respectively. The results from the combined
analysis were significantly higher when compared with
the fast dynamic analysis for both readers (P=0.01 and
P=0.02). This was also found for the slow dynamic
analysis (P=0.02 for both readers). The ROC curves are
presented in Fig. 3.
In the group of lesions of 2 cm and smaller, the slow
dynamic analyses resulted in an AUC of 0.87 (95% CI=
0.75–0.95) for reader 1 and 0.79 (95% CI = 0.67-0.91) for
reader 2. Overall, the fast analyses resulted in this group in
an AUC of 0.83 (95% CI = 0.70–0.92) and 0.85 (95% CI =
0.72–0.93), respectively. No significant difference was
found between the slow and fast dynamic analyses for both
readers (P=0.54 and P=0.41). The combined analysis
resulted in an AUC of 0.97 (95% CI = 0.88–0.99) and 0.94
(95% CI= 0.84–0.99), respectively. The results from the
combined analysis were significantly higher when com-
pared with the fast dynamic analysis for both readers (P<
0.01 and P=0.04). This was also found when compared to
the slow dynamic analysis (P=0.03 and P<0.01).
No significant differences were found between the two
readers in any of the analyses. An example of a benign and
a malignant lesion is presented in Figs. 4 and 5.
Fig. 3 ROC curve for reader 1
(a) and reader 2 (b) displaying
the fast dynamic, slow dynamic
and combined analysis. No sig-
nificant differences were found
between the fast and slow dy-
namic analysis in both readers.
A significant difference was
found between the slow dy-
namic analysis and the com-
bined analysis for both readers
(P=0.02 for both readers). The
comparison between the fast
dynamic analysis and the com-
bined analysis also resulted in a
significant difference for both
readers (P=0.01 and P=0.02).
No significant differences were
found between the two readers
1128Discussion
In this study, we demonstrated that the pharmacokinetic
parameters derived from fast dynamic scanning during
initial enhancement were a valuable additional tool for
the differentiation between benign and malignant breast
lesions on MRI. The pharmacokinetic parameters were
significantly higher for the malignant group compared
with the benign lesions (Table 2). The diagnostic per-
formance of the pharmacokinetic parameters was, com-
pared with the results of the slow dynamic analysis,
not significantly different. The combination of both
methods, however, did improve the diagnostic perfor-
mance significantly for both readers. These results were
also found in the subgroup analysis of smaller breast
lesions.
The slow dynamic analysis resembles the evaluation as
routinely performed in the clinical workflow in our
hospital. The performance of the workstation used in the
slow dynamic evaluation has already been investigated and
proven by Wiener et al. [27] in the evaluation of breast
lesions prior to surgical treatment. Schnall et al. [4]
evaluated the performance of both dynamic and morpho-
logical features in 854 women with 995 lesions. The results
of their multivariate evaluation based on both morpholog-
ical and relatively slow dynamic lesion characteristics
resulted in a similar diagnostic accuracy (AUC values of
0.87 and 0.88) compared with the results obtained in the
slow dynamic analyses of our study (0.85 and 0.83). Our
results found in the slow dynamic analysis are, therefore,
considered representative for the diagnostic performance of
an experienced radiologist in this group of patients.
Fig. 4 a Transverse reconstruction of the high-resolution subtrac-
tion sequence of the right breast. b Time versus relative enhance-
ment curve of the slow dynamic series. K
trans (c) and V (d) color
overlay images of the right breast, including a scalar bar,t o
demonstrate the parameter values. The subtraction image shows a
rounded, mostly sharp delineated lesion. The time versus signal
intensity curve demonstrates a type 1 curve, indicative for a benign
lesions. The readers classified this lesion as benign (BI-RADS 2) or
probably benign needing follow up (BI-RADS 3) based on the slow
dynamic analysis. The K
trans and V parameter color overlays
demonstrate relatively low values for both parameters (see Table 2
for comparison) indicative for a benign lesion. Histopathology
proved this lesion to be a fibroadenoma
1129In the fast dynamic analysis, both the morphologic
characteristics and slow dynamic characteristics were not
included in the evaluation; instead, a quantitative analysis
of pharmacokinetic parameters was used based on manual
ROI placement within the lesion. In the literature, both a
“hot-spot” and “whole-tumor method for ROI placement
are reported [36]. In this study, we used a hot-spot method.
The importance of a consistent ROI placing strategy has
been described by Liney et al. [36]. In our study, both
readers were instructed with a simple ROI-placing strategy
placing the ROI in an area with the highest parameter
values guided by color overlays. Since no significant
differences were found in the ROC analyses in any of the
pharmacokinetic parameters used it is assumed that the
performance of the fast dynamic analysis was not
negatively affected by this manual ROI selection strategy.
The optimal strategy of ROI selection within a breast lesion
is a subject that still needs to be further investigated; this is
beyond the scope of this study.
Gibbs et al. [24] found the use of quantitative pharma-
cokinetic parameters in the evaluation of sub 1-cm breast
lesions to be beneficial. In their study of 43 women, a
diagnostic accuracy of 0.92 was found combining the
postcontrast images with the dynamic data in a logistic
regression analysis. The exchange rate constant was found
to be the best individual parameter with a diagnostic
accuracy of 0.74. The K
trans was also found to be the best
individual parameter in our study with a diagnostic
accuracy of 0.82. Furman-Haran et al. [18] concluded in
their study of 141 lesions that the quantitative evaluation of
Fig. 5 a Transverse reconstruction of the high-resolution subtrac-
tion sequence of the right breast. b Time versus relative enhance-
ment curve of the slow dynamic series. K
trans (c) and V (d) color
overlay images of the right breast, including a scalar bar,
demonstrates the parameter values. The subtraction image shows a
spiculated lesion retromammillar. The time versus signal intensity
curve demonstrates a type 3 curve (wash-out) suggestive for a
malignancy. Both readers classified this lesion as malignant (BI-
RADS 4) based on the slow dynamic analysis. The K
trans and V
parameter color overlays demonstrate high values for both
parameters (see Table 2 for comparison), indicative for a malignant
lesion. Histopathology proved this lesion to be an invasive ductal
carcinoma
1130perfusion parameters should be able to improve breast
cancer diagnosis on MRI. In their study the K
trans was also
found to be the best discriminating parameter. Their
analysis showed results of invasive ductal carcinoma
versus fibroadenomas or fibrocystic changes. Unlike our
study, the pharmacokinetic parameters used by Furman-
Haran and coworkers were derived from high-resolution
images with relatively a low temporal resolution of 2 min.
Although our analysis used a more diverse histological
distribution (Table 1) compared with the results presented
by Furman-Haran et al. [18], only a relatively small number
of benign lesions could be included. The diverse histolog-
ical distribution also resulted in the inclusion of benign
lesions that do not necessarily cause a diagnostic dilemma
in daily practice. This can be seen as a limitation of our
study. In the subgroup analysis of smaller lesions, a more
equal distribution between benign and malignant lesions
was found. The analysis performed in this subgroup also
proved the additional value of the fast dynamic analysis in
classifying small breast lesions on MRI.
The three-time-point method used by Kelcz et al. [37]
provides the reader with a composite image showing
contrast uptake and wash-out characteristics related to the
product of microvessel surface area and permeability, as
well as to the extracellular volume fraction. In their study,
the observers correctly diagnosed 27 of 31 malignant and
31 of 37 benign lesions (sensitivity 87%; specificity 84%)
using the three-time-point method. The evaluation based
on wash-in and wash-out curves in combination with
morphology resulted in a sensitivity of 93% and a
specificity of 82%. Our results not only demonstrate a
similar performance of the pharmacokinetic analysis
compared with the evaluation based on morphology and
slow dynamics but also demonstrate the potential gain if
both methods are combined. The results presented by
Kelcz et al. [37] are, like other authors, again derived from
high spatial resolution images with a relatively low
temporal resolution of 2 min compared with our fast
dynamic scanning protocol.
With a scanning protocol using only the fast dynamic
evaluation and morphology the scantime could be reduced
significantly when compared with a protocol including the
evaluation of wash-out. This without loss of diagnostic
performance when compared with the results of the slow
dynamic analysis in our study and the results presented by
other authors [4, 12, 18]. This reduction of scantime can in
the future contribute to the cost-effectiveness of MRI
screening. However, since the highest diagnostic perfor-
mance was obtained by combining both the fast and slow
dynamic analysis, further studies are needed before the
scantime can be reduced.
The results presented in this study are our initial results
using this scanning protocol. Therefore, no cut of values
for the differentiation between benign and malignant
lesions from the pharmacokinetic parameters were used
in the evaluation or can be provided at this point. The
results presented only show the potential of our method in
differentiation between benign and malignant lesions in
this group of patients. The value of our method needs to be
further studied in a larger group, preferably using a more
even distribution between benign and malignant cases and
with lesions that can be classified on imaging as a BI-
RADS 3 or higher.
Unfortunately, the study design used did not allow a
multivariate analysis combining the fast dynamic data with
morphological characteristics. Also, the possible trade-off
between the pharmacokinetic parameters based on initial
enhancement and the wash-out based on late dynamic
characteristics cannot be derived from these data. Both
analyses will need to be performed in future projects in
order to evaluate the full potential of the fast dynamic
analysis as used in our study.In conclusion, pharmacoki-
netic parameters derived from fast dynamic imaging during
initial enhancement have great potential in classifying
enhancing lesions in the breast. In this study, the diagnostic
performance for the fast dynamic analysis proved to be
equal to the results of experienced radiologists using more
common evaluation methods based on morphologic
characteristics and slow dynamic enhancement character-
istics. An increased diagnostic performance was found in
combining both methods. This shows the additional value
of this method in further improving the diagnostic accuracy
of breast MRI.
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